Which IVF stimulation is easier on patients? new study aims to find out

NCT ID NCT06175832

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two different ovarian stimulation methods used in IVF to see which one patients prefer and tolerate better. Sixty women undergoing either fertility preservation or preimplantation genetic testing will try both methods in a crossover design. The main goal is to measure treatment-related quality of life and satisfaction through questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Corifollitropin alfa (Elonva), recombinant FSH (Puregon), GnRH antagonist (Orgalutran), GnRH agonist (Gonapeptyl), progestin (Cerazette)
What this could lead to
If this trial succeeds, it could help identify which ovarian stimulation method is more comfortable and convenient for patients undergoing IVF or fertility preservation.
What could go wrong
This is a small, single-center phase 4 study with only 60 participants, so results may not apply to everyone. The focus is on patient satisfaction, not pregnancy or live birth rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FERTILITY PRESERVATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital Ghent

    RECRUITING

    Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.